Back to search
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Multiple Myeloma
Clinicaltrials.gov:
EU CTIS:
#2023-505530-10-00
EudraCT:
J&J ID:
#CR109123
Other:
#68284528MMY4002
Interested in this trial?
Subscribe or share this trial
Trials at a glance
Status
Enrolling
Condition
Multiple Myeloma
Trial type
Interventional
Trial phase
Phase 4
Investigational
product
product
Cilta-cel
Age
18+ years old
Biological sex
All
Placebo?
No
Trial start date
March 9, 2022
Trial end date
October 30, 2037
CT.gov ID
#NCT05201781
Share the trial ID with your doctor to see if trial participation is right for you. Participation depends on an independent medical assessment.
Countries:
- Belgium,
- China,
- France,
- Israel,
- Japan,
- Netherlands,
- Spain,
- United States
Loading...
Enrolling
Detroit, Michigan, United States, 48201
Enrolling
Boston, Massachusetts, United States, 02215
Enrolling
Nord, France, 59037
Enrolling
Duarte, California, United States, 91010
Enrolling
Pamplona, Spain, 31008
Enrolling
Boston, Massachusetts, United States, 02115
Enrolling
Atlanta, Georgia, United States, 30322
Enrolling
Milwaukee, Wisconsin, United States, 53226
Enrolling
Hackensack, New Jersey, United States, 07601
Enrolling
Paris, France, 75010
Enrolling
Salamanca, Spain, 37007
Enrolling
Indianapolis, Indiana, United States, 46202
Enrolling
Westwood, Kansas, United States, 66205
Enrolling
Charlotte, North Carolina, United States, 28204
Enrolling
Houston, Texas, United States, 77030
Enrolling
Boston, Massachusetts, United States, 02215
Enrolling
Phoenix, Arizona, United States, 85054
Enrolling
Rochester, Minnesota, United States, 55902
Enrolling
New York, New York, United States, 10065
Enrolling
Tampa, Florida, United States, 33612
Enrolling
The Bronx, New York, United States, 10467
Enrolling
New York, New York, United States, 10029
Enrolling
Chicago, Illinois, United States, 60611
Enrolling
Buffalo, New York, United States, 14263
Enrolling
New Brunswick, New Jersey, United States, 08903
Enrolling
Nashville, Tennessee, United States, 37203
Enrolling
Stanford, California, United States, 94305-5623
Enrolling
Tel Aviv, Israel, 64239
Enrolling
Ghent, Belgium, 9000
Enrolling
Leuven, Belgium, 3000
Enrolling
Groningen, Netherlands, 9713 GZ
Enrolling
San Francisco, California, United States, 94143
Enrolling
Chicago, Illinois, United States, 60637
Enrolling
Philadelphia, Pennsylvania, United States, 19104
Enrolling
Pittsburgh, Pennsylvania, United States, 15232
Enrolling
Amsterdam, Netherlands, 1081 HV
Enrolling
St Louis, Missouri, United States, 63110
Enrollment complete
Hangzhou, China, 310003
Enrollment complete
Fuzhou, China, 350000
Enrollment complete
Shibuya City, Japan, 150-8935
Enrollment complete
Nanjing, China, 210029
Enrollment complete
Nagoya, Japan, 467 8602
Enrollment complete
Nanjing, China, 210008
Enrollment complete
Beijing, China, 100191
Enrollment complete
Shanghai, China, 200025
Enrollment complete
Shanghai, China, 200003
Enrollment complete
Shanghai, China, 200434
Enrollment complete
Guangzhou, China, 510060
Enrollment complete
Xi'an, China, 710004
Enrollment complete
Chengdu, China, 610041
#
More than 50 sites in this region
#
More than 10 sites in this region
#
Less than 10 sites in this region
Individual sites
Access detailed information on the trial:
Clinical trials information
© Johnson & Johnson and its affiliates 2026
